
|Videos|August 4, 2020
Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD (ASRS 2020)
Author(s)Alex Delaney-Gesing , David Hutton
Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."
Advertisement
Justis P. Ehlers, MD, of the Cole Eye Institute at the Cleveland Clinic, speaks with Ophthalmology Times®' David Hutton on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)" during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
DAYBREAK: Tarcocimab, tabirafusp-ted noninferior to aflibercept in wet AMD
2
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
3
Myopia-related retinal detachments in younger patients: A retina view
4
Nimesh Patel, MD, on low-dose atropine and SYD-101
5












